EAU Prostate Cancer Risk Groups
ورودیهای بالینی بیمار
حداقل ۰.۱ — حداکثر ۲۰۰ • واحد: ng/mL
حداقل ۱ — حداکثر ۵
پارامترهای بالینی بیمار را در فرم روبرو وارد کنید و روی «محاسبه» کلیک نمایید تا نمره، طبقه خطر و اقدامات فوری نمایش داده شوند.
- grouped≥ 0
The EAU Prostate Cancer Risk Groups calculates evaluating lower urinary tract symptoms, nephrolithiasis burden, and prostate cancer risk. Key inputs include psa. Scores guide initiating medical expulsive or alpha-blocker therapy, ordering renal imaging, or scheduling surgical intervention. This standardized assessment improves clinical decision safety and bedside patient management.
Clinical Guidelines & Evidence
EAU localized prostate cancer risk stratification.
Clinical Indication
The EAU Prostate Cancer Risk Groups is indicated for bedside clinical practice to support EAU localized prostate cancer risk stratification.. It assists healthcare providers in standardizing clinical assessment and therapeutic decision-making.
Target Population
Target population comprises Patients presenting with renal colic, hematuria, benign prostatic hyperplasia (BPH), or urogenital malignancies. Clinical application is indicated across Urology clinics, shock wave lithotripsy suites, and acute urologic surgical services.
Limitations & Contraindications
Serum PSA levels can be transiently elevated by acute prostatitis, urinary retention, or recent instrumentation.
Clinical Pearls & Action Plan
Obstructive urolithiasis complicated by upper urinary tract infection represents a surgical emergency requiring urgent decompression.
Low: PSA<10 and ISUP 1 and cT1-2a; Intermediate: PSA 10-20 or ISUP 2-3 or cT2b; High: PSA>20 or ISUP 4-5 or cT2c+
Input Parameters
| Name | Type | Required | Description |
|---|---|---|---|
| psa | float | Yes | PSA(ng/mL) |
| isup | integer | Yes | ISUP grade group |
Score Interpretation & Guidance
| Range | Stage | Description |
|---|---|---|
| ≥ 0 | grouped | Risk group |
Evidence-Based References (EBM)
- Mottet N, et al. EAU Guidelines on Prostate Cancer. 2023 update.